Pegbelfermin治疗非酒精性脂肪性肝炎伴代偿性肝硬化患者(FALCON 2):一项随机2b期研究
FALCON 2是一项随机、双盲、安慰剂对照2b期研究,纳入155例经活检确诊的非酒精性脂肪性肝炎(NASH)伴4期纤维化患者,每周皮下注射Pegbelfermin 10、20或40 mg或安慰剂48周。第48周时Pegbelfermin组24%至28%达到主要终点,安慰剂组为31%(P=0.361),研究未达到主要终点;Pegbelfermin总体耐受性良好。
要点
- Pegbelfermin 10、20、40 mg组主要终点应答率24%至28%,安慰剂组31%,差异无统计学意义(P=0.361)。
- Pegbelfermin组非酒精性脂肪性肝病活动度评分改善更常见,主要源于小叶炎症减轻。
- Pegbelfermin组严重不良事件更频繁,但均与治疗无关;1例40 mg组因腹水加重停药。
核心结论
- FALCON 2未达到主要终点,即经活检评估的NASH临床研究网络纤维化评分改善1级或以上且NASH无恶化。
- Pegbelfermin在该晚期NASH人群中总体耐受性良好。
研究设计与样本
- FALCON 2(NCT03486912)为随机(1:1:1:1)、双盲、安慰剂对照2b期研究。
- 纳入经活检确诊的NASH伴4期纤维化成人患者,Pegbelfermin 10、20或40 mg或安慰剂每周皮下注射一次,治疗48周。
- 共155例患者随机,154例接受治疗。
主要发现
- 第48周时,Pegbelfermin组24%至28%达到主要终点,安慰剂组为31%(P=0.361)。
- Pegbelfermin组非酒精性脂肪性肝病活动度评分改善较安慰剂组更常见,主要源于小叶炎症减轻。
- Pegbelfermin组肝脏硬度(磁共振弹性成像)和脂肪变(磁共振成像-质子密度脂肪分数)改善比例在数值上高于安慰剂组,但差异无统计学意义。
- 20 mg和/或40 mg Pegbelfermin组III型前胶原N端前肽、丙氨酸氨基转移酶和天冬氨酸氨基转移酶均值在数值上低于安慰剂组。
- Pegbelfermin组严重不良事件较安慰剂组更频繁,但均与治疗无关;1例40 mg组患者因治疗中出现的不良事件(腹水加重)停药。
关键数值与推荐
- 主要终点为第48周时NASH临床研究网络纤维化评分改善1级或以上且NASH无恶化。
- Pegbelfermin剂量反应采用Cochran-Armitage趋势检验评估比例,单侧α=0.05。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Pegbelfermin is a polyethylene glycol-conjugated analog of human fibroblast growth factor 21, a nonmitogenic hormone that regulates energy metabolism. This phase 2b study evaluated 48-week pegbelfermin treatment in patients with nonalcoholic steatohepatitis (NASH) with compensated cirrhosis. METHODS: FALCON 2 (NCT03486912) was a randomized (1:1:1:1), double-blind, placebo-controlled study. Eligible adults had biopsy-confirmed NASH and stage 4 fibrosis. Pegbelfermin (10, 20, or 40 mg) or placebo was injected subcutaneously once weekly. The primary endpoint was 1 or more stages of improvement in the NASH Clinical Research Network fibrosis score without NASH worsening at week 48; pegbelfermin dose response was assessed using a Cochran-Armitage trend test across proportions (1-sided α = .05). Additional endpoints included histologic and noninvasive measures of steatosis, fibrosis, and liver injury/inflammation. RESULTS: Overall, 155 patients were randomized, and 154 patients received treatment. At week 48, 24% to 28% of the pegbelfermin arms had primary endpoint responses vs 31% of the placebo arm (P = .361). Nonalcoholic fatty liver disease activity score improvements were more frequent with pegbelfermin vs placebo and were driven primarily by reduced lobular inflammation. Numerically higher proportions of the pegbelfermin arms had liver stiffness (magnetic resonance elastography) and steatosis (magnetic resonance imaging-proton density fat fraction) improvements vs placebo; these differences were not statistically significant. Mean N-terminal type III collagen propeptide, alanine aminotransferase, and aspartate aminotransferase values were numerically lower in the 20- and/or 40-mg pegbelfermin arms compared with placebo. Serious adverse events were more frequent with pegbelfermin vs placebo, although none were treatment related. One patient (40-mg pegbelfermin) discontinued treatment because of a treatment-emergent adverse event (worsening ascites). CONCLUSIONS: FALCON 2 did not meet its primary endpoint of 1 or more stages of improvement in the NASH Clinical Research Network fibrosis without NASH worsening assessed via biopsy. Pegbelfermin generally was well tolerated in this advanced NASH population.
引用
- Abdelmalek MF, Sanyal AJ, Nakajima A, et al. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study. Clin Gastroenterol Hepatol. 2023. PMID: 37088458. doi:10.1016/j.cgh.2023.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。